Company news

Viking Therapeutics, Inc. news in 2026

Viking Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Viking Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

October 28, 2026

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

October 21, 2026

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

October 14, 2026

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6, 2026

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

September 28, 2026

Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes

September 23, 2026

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

September 22, 2026

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

July 29, 2026

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

July 23, 2026

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

July 22, 2026

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

June 24, 2026

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

June 11, 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

May 5, 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 29, 2026

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

April 22, 2026

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

March 25, 2026

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

February 11, 2026

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

February 4, 2026

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

January 11, 2026

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

January 7, 2026

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

January 6, 2026

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026